What is the Wockhardt Ltd share price today?

The share price of NSE:WOCKPHARMA-EQ on 07 Sep 2026 (as of 11:00:35 IST) is ₹2182.10.

What is the NSE:WOCKPHARMA-EQ 52 week high low price?

Over the past 52 weeks (as of 07 Sep 2026), the NSE:WOCKPHARMA-EQ 52 week high low range shows a high of ₹2422.30 and a low of ₹1086.70.

What is the Wockhardt Ltd market cap?

As on 07 Sep 2026, Wockhardt Ltd market cap is ₹33908.10 Cr.

What is the shareholding pattern of Wockhardt Ltd Stock?

The shareholding pattern of Wockhardt Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 49.08% Foreign Institutional Investors (FII): 7.22% Domestic Institutional Investors (DII): 2.44% Mutual Funds: 6.79% Retail & Others: 34.47% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Wockhardt Ltd?

The Price-to-Earnings (PE) ratio of Wockhardt Ltd is 82.90, and the Price-to-Book (PB) ratio is 3.87, as on 07 Sep 2026.

Wockhardt Share Price

2287.70-42.00 (-1.80%)

+54.90% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

-1.80%

1 Week

+9.66%

1 Month

+20.43%

3 Month

+16.41%

6 Month

+92.32%

YTD

+58.19%

1 Year

+54.90%

5 Year

+428.34%

10 Year

+158.80%

Max

+707.43%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

2265.00

2090.00

1833.30

1792.40

1162.10

1086.70

High

2334.50

2360.00

2422.30

About

Wockhardt is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

ZYDUSLIFENSE

CIPLANSE

LAURUSLABSNSE

MANKINDNSE

DRREDDYNSE

AUROPHARMANSE

LUPINNSE

WOCKPHARMANSE

LTP

1W Low

1W High

Market cap (₹)

1849.9+12.6 (0.69%)

1832.20

1891.50

4,47,476Cr

9602+227 (2.42%)

9312.50

9740

2,54,764Cr

4928.5+88.5 (1.83%)

4848.50

5010

1,89,423Cr

1180.3+20.3 (1.75%)

1152.10

1190.60

1,16,658Cr

1399+4.5 (0.32%)

1364.50

1419

1,11,484Cr

2026.2+72.2 (3.69%)

1963.80

2055.30

1,09,943Cr

2500+199.3 (8.66%)

2303

2504.30

1,01,712Cr

1200.4+15.4 (1.30%)

1185

1222

1,01,005Cr

1716-18 (-1.04%)

1689.30

1740

99,253Cr

2100.7+17.7 (0.85%)

2080

2135

96,031Cr

2287.7+201.6 (9.66%)

2090

2360

37,857Cr

Wockhardt Share Price

2287.70-42.00 (-1.80%)

+54.90% past 1 Year

Financial overview

Compounded Sales Growth

10 years-3%

5 years4%

3 years8%

Last year12%

Compounded Profit Growth

10 years-2%

5 years-21%

3 years-

Last year449%

Stock Price CAGR

10 years10%

5 years40%

3 years116%

1 year54%

Return on Equity

10 years-9%

5 years-7%

3 years-4%

Last year4%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-3%	4%	8%	12%
-2%	-21%	-	449%
10%	40%	116%	54%
-9%	-7%	-4%	4%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

ZYDUSLIFE

CIPLA

LAURUSLABS

MANKIND

DRREDDY

AUROPHARMA

LUPIN

WOCKPHARMA

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,849.9	₹447476 Cr	37	12.07	62.82	₹11479 Cr
9,602	₹254764 Cr	87.1	34.04	128.41	₹2568 Cr
4,928.5	₹189423 Cr	86.85	16.72	97.06	₹2163 Cr
1,180.3	₹116658 Cr	25.85	9.42	62.53	₹5040 Cr
1,399	₹111484 Cr	33.08	9.77	57.87	₹3879 Cr
2,026.2	₹109943 Cr	100.55	6.8	29.25	₹889 Cr
2,500	₹101712 Cr	49.79	13.75	71.08	₹1913 Cr
1,200.4	₹101005 Cr	31.35	5.32	63.99	₹4196 Cr
1,716	₹99253 Cr	26.73	17.95	96.84	₹3505 Cr
2,100.7	₹96031 Cr	17.37	30.95	154.35	₹5333 Cr
2,287.7	₹37857 Cr	92.56	6.54	39.08	₹213 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Minority Interest

Secured Loans

Unsecured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Less Impairment of Assets

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010	Dec 2008	Dec 2007
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹81 Cr	₹81 Cr	₹77 Cr	₹72 Cr	₹72 Cr	₹55 Cr	₹55 Cr	₹55 Cr	₹55 Cr	₹55 Cr	₹55 Cr	₹354 Cr	₹353 Cr	₹353 Cr	₹816 Cr	₹800 Cr	₹723 Cr	₹55 Cr	₹55 Cr
₹13 Cr	₹11 Cr	₹13 Cr	₹16 Cr	₹18 Cr	₹28 Cr	₹30 Cr	₹32 Cr	₹37 Cr	₹37 Cr	₹29 Cr	₹46 Cr	₹45 Cr	₹32 Cr	₹10 Cr	₹0	₹0	₹0	₹0
₹4846 Cr	₹4261 Cr	₹3269 Cr	₹3266 Cr	₹3759 Cr	₹3293 Cr	₹2586 Cr	₹2587 Cr	₹2760 Cr	₹3244 Cr	₹3691 Cr	₹3316 Cr	₹3183 Cr	₹2319 Cr	₹645 Cr	₹143 Cr	-₹52 Cr	₹963 Cr	₹1219 Cr
₹4846 Cr	₹4261 Cr	₹3269 Cr	₹3266 Cr	₹3759 Cr	₹3293 Cr	₹2586 Cr	₹2587 Cr	₹2760 Cr	₹3244 Cr	₹3691 Cr	₹3316 Cr	₹3183 Cr	₹2319 Cr	₹645 Cr	₹143 Cr	-₹52 Cr	₹963 Cr	₹1219 Cr
₹4940 Cr	₹4353 Cr	₹3359 Cr	₹3354 Cr	₹3849 Cr	₹3376 Cr	₹2672 Cr	₹2675 Cr	₹2852 Cr	₹3337 Cr	₹3775 Cr	₹3715 Cr	₹3581 Cr	₹2704 Cr	₹1471 Cr	₹943 Cr	₹672 Cr	₹1018 Cr	₹1274 Cr
₹341 Cr	₹304 Cr	₹303 Cr	₹308 Cr	₹353 Cr	₹383 Cr	₹386 Cr	₹330 Cr	₹346 Cr	₹382 Cr	₹465 Cr	₹144 Cr	₹136 Cr	₹0	₹0	₹0	₹0	₹0	₹0
₹769 Cr	₹274 Cr	₹0	₹222 Cr	₹260 Cr	₹500 Cr	₹1237 Cr	₹1653 Cr	₹2168 Cr	₹2887 Cr	₹1647 Cr	₹1180 Cr	₹1096 Cr	₹1468 Cr	₹2697 Cr	₹2785 Cr	₹3552 Cr	₹3161 Cr	₹2344 Cr
₹749 Cr	₹937 Cr	₹891 Cr	₹2 Cr	₹95 Cr	₹3 Cr	₹3 Cr	₹238 Cr	₹5 Cr	₹303 Cr	₹273 Cr	₹5 Cr	₹6 Cr	₹8 Cr	₹9 Cr	₹9 Cr	₹465 Cr	₹1074 Cr	₹556 Cr
-₹440 Cr	-₹514 Cr	-₹544 Cr	-₹576 Cr	-₹545 Cr	-₹370 Cr	-₹398 Cr	-₹242 Cr	-₹149 Cr	-₹133 Cr	-₹98 Cr	₹53 Cr	₹7 Cr	-₹24 Cr	₹101 Cr	-₹75 Cr	-₹48 Cr	-₹42 Cr	₹92 Cr
₹117 Cr	₹161 Cr	₹242 Cr	₹304 Cr	₹419 Cr	₹279 Cr	₹307 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹40 Cr	₹29 Cr	₹28 Cr	₹26 Cr	₹32 Cr	₹84 Cr	₹46 Cr	₹53 Cr	₹65 Cr	₹94 Cr	₹71 Cr	₹635 Cr	₹52 Cr	₹70 Cr	₹84 Cr	₹224 Cr	₹0	₹0	₹0
₹1235 Cr	₹887 Cr	₹617 Cr	-₹22 Cr	₹261 Cr	₹496 Cr	₹1195 Cr	₹1703 Cr	₹2089 Cr	₹3151 Cr	₹1893 Cr	₹1872 Cr	₹1161 Cr	₹1521 Cr	₹2892 Cr	₹2944 Cr	₹3970 Cr	₹4194 Cr	₹2992 Cr
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹563 Cr	₹592 Cr	₹766 Cr	₹867 Cr	₹921 Cr	₹696 Cr	₹895 Cr	₹840 Cr	₹602 Cr	₹534 Cr	₹638 Cr	₹553 Cr	₹558 Cr	₹634 Cr	₹541 Cr	₹437 Cr	₹435 Cr	₹523 Cr	₹451 Cr
₹581 Cr	₹886 Cr	₹1144 Cr	₹1172 Cr	₹1197 Cr	₹1230 Cr	₹1568 Cr	₹1353 Cr	₹1548 Cr	₹690 Cr	₹621 Cr	₹844 Cr	₹948 Cr	₹790 Cr	₹978 Cr	₹1069 Cr	₹364 Cr	₹333 Cr	₹380 Cr
₹438 Cr	₹496 Cr	₹832 Cr	₹1330 Cr	₹1034 Cr	₹1066 Cr	₹904 Cr	₹562 Cr	₹437 Cr	₹663 Cr	₹550 Cr	₹348 Cr	₹210 Cr	₹182 Cr	₹261 Cr	₹390 Cr	₹0	₹0	₹0
₹40 Cr	₹68 Cr	₹49 Cr	₹66 Cr	₹55 Cr	₹129 Cr	₹130 Cr	₹109 Cr	₹105 Cr	₹92 Cr	₹33 Cr	₹28 Cr	₹28 Cr	₹167 Cr	₹111 Cr	₹24 Cr	₹232 Cr	₹774 Cr	₹81 Cr
₹1622 Cr	₹2042 Cr	₹2791 Cr	₹3435 Cr	₹3207 Cr	₹3121 Cr	₹3497 Cr	₹2864 Cr	₹2692 Cr	₹1979 Cr	₹1842 Cr	₹1773 Cr	₹1743 Cr	₹1773 Cr	₹1891 Cr	₹1919 Cr	₹1031 Cr	₹1630 Cr	₹911 Cr
₹8138 Cr	₹7586 Cr	₹7070 Cr	₹7075 Cr	₹7670 Cr	₹7376 Cr	₹7749 Cr	₹7571 Cr	₹7978 Cr	₹8849 Cr	₹7976 Cr	₹7505 Cr	₹6622 Cr	₹5998 Cr	₹6254 Cr	₹5806 Cr	₹5673 Cr	₹6842 Cr	₹5177 Cr
₹768 Cr	₹770 Cr	₹882 Cr	₹866 Cr	₹840 Cr	₹639 Cr	₹641 Cr	₹473 Cr	₹576 Cr	₹639 Cr	₹274 Cr	₹295 Cr	₹267 Cr	₹80 Cr	₹47 Cr	₹503 Cr	₹1052 Cr	₹572 Cr	₹142 Cr
₹2125 Cr	₹1859 Cr	₹2112 Cr	₹1887 Cr	₹1862 Cr	₹2332 Cr	₹3213 Cr	₹3375 Cr	₹3748 Cr	₹4160 Cr	₹2677 Cr	₹2010 Cr	₹1906 Cr	₹2070 Cr	₹3493 Cr	₹3852 Cr	₹4018 Cr	₹4235 Cr	₹2900 Cr
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹6164 Cr	₹5814 Cr	₹5721 Cr	₹5696 Cr	₹6019 Cr	₹5656 Cr	₹6703 Cr	₹6113 Cr	₹5772 Cr	₹5456 Cr	₹4377 Cr	₹4553 Cr	₹4643 Cr	₹4296 Cr	₹4212 Cr	₹4049 Cr	₹3834 Cr	₹3990 Cr	₹3410 Cr
₹3373 Cr	₹3078 Cr	₹2840 Cr	₹2654 Cr	₹2557 Cr	₹2313 Cr	₹3201 Cr	₹3055 Cr	₹2884 Cr	₹2684 Cr	₹1568 Cr	₹2430 Cr	₹2348 Cr	₹1685 Cr	₹1307 Cr	₹1439 Cr	₹1039 Cr	₹988 Cr	₹860 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹621 Cr	₹334 Cr	₹29 Cr	₹266 Cr	₹5 Cr	₹0
₹2791 Cr	₹2736 Cr	₹2881 Cr	₹3042 Cr	₹3462 Cr	₹3343 Cr	₹3502 Cr	₹3058 Cr	₹2888 Cr	₹2773 Cr	₹2809 Cr	₹2123 Cr	₹2295 Cr	₹1990 Cr	₹2571 Cr	₹2580 Cr	₹2529 Cr	₹2996 Cr	₹2549 Cr
₹671 Cr	₹513 Cr	₹434 Cr	₹414 Cr	₹389 Cr	₹603 Cr	₹836 Cr	₹900 Cr	₹1039 Cr	₹971 Cr	₹928 Cr	₹1007 Cr	₹708 Cr	₹491 Cr	₹499 Cr	₹510 Cr	₹708 Cr	₹634 Cr	₹445 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹45 L	₹45 L	₹45 L	₹45 L	₹45 L	₹3 Cr	₹3 Cr	₹3 Cr	₹91 Cr	₹90 Cr	₹95 Cr	₹93 Cr	₹71 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹45 L	₹45 L	₹45 L	₹45 L	₹45 L	₹3 Cr	₹3 Cr	₹3 Cr	₹91 Cr	₹90 Cr	₹95 Cr	₹93 Cr	₹71 Cr
₹251 Cr	₹246 Cr	₹266 Cr	₹269 Cr	₹259 Cr	₹228 Cr	₹231 Cr	₹251 Cr	₹275 Cr	₹295 Cr	₹175 Cr	₹846 Cr	₹236 Cr	₹183 Cr	₹208 Cr	₹371 Cr	₹0	₹0	₹0
₹20 Cr	₹2 Cr	₹17 Cr	₹17 Cr	₹18 Cr	₹1 Cr	₹2 Cr	₹1 Cr	₹3 Cr	₹1 Cr	₹3 Cr	₹5 Cr	₹25 Cr	₹5 Cr	₹0	₹0	₹0	₹0	₹0
₹5441 Cr	₹5017 Cr	₹4886 Cr	₹4867 Cr	₹5081 Cr	₹4951 Cr	₹5320 Cr	₹4756 Cr	₹4599 Cr	₹4314 Cr	₹4024 Cr	₹3983 Cr	₹3266 Cr	₹2672 Cr	₹3772 Cr	₹3904 Cr	₹3332 Cr	₹3723 Cr	₹3142 Cr
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹412 Cr	₹422 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹213 Cr	₹562 Cr	₹0	₹339 Cr	₹574 Cr	₹0	₹0	₹0	₹0	₹0	₹0
₹887 Cr	₹725 Cr	₹640 Cr	₹658 Cr	₹769 Cr	₹799 Cr	₹716 Cr	₹819 Cr	₹856 Cr	₹1108 Cr	₹1102 Cr	₹1021 Cr	₹993 Cr	₹1059 Cr	₹889 Cr	₹714 Cr	₹765 Cr	₹830 Cr	₹772 Cr
₹588 Cr	₹661 Cr	₹618 Cr	₹797 Cr	₹918 Cr	₹918 Cr	₹1243 Cr	₹1274 Cr	₹962 Cr	₹1034 Cr	₹1111 Cr	₹741 Cr	₹481 Cr	₹958 Cr	₹759 Cr	₹605 Cr	₹574 Cr	₹853 Cr	₹670 Cr
₹250 Cr	₹191 Cr	₹529 Cr	₹124 Cr	₹406 Cr	₹292 Cr	₹268 Cr	₹449 Cr	₹1082 Cr	₹1604 Cr	₹1478 Cr	₹1235 Cr	₹1126 Cr	₹1096 Cr	₹700 Cr	₹483 Cr	₹347 Cr	₹650 Cr	₹380 Cr
₹73 Cr	₹4 Cr	₹0	₹0	₹0	₹0	₹98 L	₹0	₹0	₹29 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹396 Cr	₹462 Cr	₹286 Cr	₹335 Cr	₹352 Cr	₹272 Cr	₹172 Cr	₹273 Cr	₹266 Cr	₹198 Cr	₹260 Cr	₹186 Cr	₹182 Cr	₹214 Cr	₹134 Cr	₹100 Cr	₹655 Cr	₹786 Cr	₹212 Cr
₹2606 Cr	₹2465 Cr	₹2073 Cr	₹1914 Cr	₹2445 Cr	₹2281 Cr	₹2401 Cr	₹2815 Cr	₹3380 Cr	₹4535 Cr	₹3952 Cr	₹3522 Cr	₹3356 Cr	₹3327 Cr	₹2482 Cr	₹1902 Cr	₹2341 Cr	₹3119 Cr	₹2034 Cr
₹984 Cr	₹423 Cr	-₹718 Cr	-₹1521 Cr	-₹762 Cr	-₹840 Cr	-₹1097 Cr	-₹49 Cr	₹688 Cr	₹2556 Cr	₹2110 Cr	₹1749 Cr	₹1613 Cr	₹1553 Cr	₹591 Cr	-₹17 Cr	₹1310 Cr	₹1488 Cr	₹1123 Cr
₹8138 Cr	₹7586 Cr	₹7070 Cr	₹7075 Cr	₹7670 Cr	₹7376 Cr	₹7749 Cr	₹7571 Cr	₹7978 Cr	₹8849 Cr	₹7976 Cr	₹7505 Cr	₹6622 Cr	₹5998 Cr	₹6254 Cr	₹5806 Cr	₹5673 Cr	₹6842 Cr	₹5177 Cr
₹304	₹268	₹217	₹232	₹266	₹304	₹239	₹239	₹254	₹299	₹339	₹306	₹295	₹217	₹64	₹18	₹0	₹93	₹116
₹304	₹268	₹217	₹232	₹266	₹280	₹220	₹220	₹234	₹275	₹312	₹282	₹272	₹200	₹59	₹17	₹0	₹86	₹107

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Translation adjustment on reserves / op cash balalces frgn subsidiaries

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010	Dec 2008	Dec 2007
₹238 Cr	-₹16 Cr	-₹420 Cr	-₹624 Cr	-₹411 Cr	₹916 Cr	-₹197 Cr	-₹300 Cr	-₹641 Cr	-₹247 Cr	₹289 Cr	₹575 Cr	₹891 Cr	₹1860 Cr	₹577 Cr	₹104 Cr	-₹986 Cr	-₹251 Cr	₹474 Cr
₹455 Cr	₹455 Cr	₹677 Cr	₹635 Cr	₹554 Cr	-₹943 Cr	₹483 Cr	₹445 Cr	₹449 Cr	₹303 Cr	₹262 Cr	₹286 Cr	₹134 Cr	₹273 Cr	₹918 Cr	₹495 Cr	₹1078 Cr	₹976 Cr	₹167 Cr
-₹282 Cr	-₹492 Cr	-₹8 Cr	₹153 Cr	₹367 Cr	-₹143 Cr	₹380 Cr	₹80 Cr	₹278 Cr	-₹297 Cr	-₹396 Cr	-₹345 Cr	₹588 Cr	-₹267 Cr	-₹130 Cr	₹45 Cr	-₹244 Cr	-₹570 Cr	-₹198 Cr
₹411 Cr	-₹53 Cr	₹249 Cr	₹164 Cr	₹510 Cr	-₹170 Cr	₹666 Cr	₹224 Cr	₹86 Cr	-₹242 Cr	₹156 Cr	₹516 Cr	₹1612 Cr	₹1867 Cr	₹1364 Cr	₹645 Cr	-₹152 Cr	₹156 Cr	₹443 Cr
₹390 Cr	-₹22 Cr	₹219 Cr	₹153 Cr	₹413 Cr	-₹287 Cr	₹649 Cr	₹183 Cr	₹68 Cr	-₹269 Cr	₹72 Cr	₹355 Cr	₹1476 Cr	₹1532 Cr	₹1344 Cr	₹642 Cr	-₹199 Cr	₹125 Cr	₹377 Cr
-₹241 Cr	-₹783 Cr	-₹137 Cr	-₹125 Cr	-₹201 Cr	₹1470 Cr	-₹156 Cr	₹95 Cr	₹630 Cr	-₹687 Cr	-₹818 Cr	-₹207 Cr	-₹852 Cr	₹1085 Cr	-₹305 Cr	-₹277 Cr	₹704 Cr	-₹1198 Cr	-₹1668 Cr
-₹54 Cr	₹409 Cr	₹334 Cr	-₹315 Cr	-₹71 Cr	-₹1171 Cr	-₹680 Cr	-₹776 Cr	-₹769 Cr	₹1254 Cr	₹254 Cr	-₹76 Cr	-₹601 Cr	-₹2246 Cr	-₹827 Cr	-₹373 Cr	-₹396 Cr	₹1040 Cr	₹678 Cr
₹95 Cr	-₹396 Cr	₹416 Cr	-₹287 Cr	₹141 Cr	₹12 Cr	-₹186 Cr	-₹499 Cr	-₹71 Cr	₹298 Cr	-₹492 Cr	₹73 Cr	₹23 Cr	₹372 Cr	₹212 Cr	-₹8 Cr	₹110 Cr	-₹34 Cr	-₹613 Cr
₹112 Cr	₹505 Cr	₹90 Cr	₹370 Cr	₹232 Cr	₹219 Cr	₹397 Cr	₹897 Cr	₹964 Cr	₹663 Cr	₹1159 Cr	₹1102 Cr	₹1050 Cr	₹690 Cr	₹470 Cr	₹314 Cr	₹212 Cr	₹377 Cr	₹973 Cr
-₹4 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹59 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	-₹34 Cr
₹14 Cr	₹3 Cr	-₹1 Cr	₹7 Cr	-₹3 Cr	₹1 Cr	₹8 Cr	-₹1 Cr	₹4 Cr	₹2 Cr	-₹2 Cr	-₹16 Cr	₹28 Cr	-₹12 Cr	₹8 Cr	₹164 Cr	-₹8 Cr	-₹131 Cr	-₹5 Cr
₹217 Cr	₹112 Cr	₹505 Cr	₹90 Cr	₹370 Cr	₹232 Cr	₹219 Cr	₹397 Cr	₹897 Cr	₹964 Cr	₹665 Cr	₹1159 Cr	₹1102 Cr	₹1050 Cr	₹690 Cr	₹470 Cr	₹314 Cr	₹212 Cr	₹380 Cr

Fundamental Ratios

Consolidated

Standalone

Wockhardt Share Price

2287.70-42.00 (-1.80%)

+54.90% past 1 Year

Shareholding summary

Promoters

49.08%

FII

7.22%

DII

2.44%

6.79%

Others

34.47%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
49.08%	49.08%	49.08%	49.08%	49.09%	49.09%
7.22%	7.08%	6.99%	7.09%	7.28%	6.82%
2.44%	2.83%	2.78%	3.10%	2.98%	3.02%
6.79%	8.12%	7.76%	7.89%	8.02%	7.56%
34.47%	32.89%	33.39%	32.84%	32.63%	33.51%

Bulk & block deals

Name

Nk Securities Research Private Limited

Graviton Research Capital Llp

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
06 May 2026	Purchase	173.65 Cr	₹1,720	10.10 L	Bulk	0.621336	NSE
06 May 2026	Sell	173.73 Cr	₹1,720.71	10.10 L	Bulk	0.621336	NSE
01 Jan 2024	Purchase	38.58 Cr	₹456.76	8.45 L	Bulk	0.519768	NSE
01 Jan 2024	Sell	38.57 Cr	₹456.72	8.45 L	Bulk	0.519768	NSE
12 Dec 2023	Purchase	38.90 Cr	₹397.13	9.80 L	Bulk	0.602828	NSE
12 Dec 2023	Sell	38.91 Cr	₹397.26	9.80 L	Bulk	0.602828	NSE
11 Dec 2023	Purchase	34.20 Cr	₹373.22	9.16 L	Bulk	0.563916	NSE
11 Dec 2023	Sell	34.16 Cr	₹372.83	9.16 L	Bulk	0.563916	NSE
17 Nov 2023	Purchase	37.29 Cr	₹324.81	11.48 L	Bulk	0.706558	NSE
17 Nov 2023	Sell	37.33 Cr	₹325.17	11.48 L	Bulk	0.706558	NSE

Insider trading & SAST

Client name

Muayyad Khorakiwala

Themisto Trustee Company Pvt Ltd

Themisto Trustee Company Private Limited

Themisto Trustee Company Private Ltd

Themisto Trustee Company Pvt Ltd

Themisto Trustee Company Pvt. Ltd.

Themisto Trustee Company Private Ltd As Trustee

Themisto Trustee Company Private Ltd

Themsio Trustee Company Pvt Ltd

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
27 Dec 2024	Immediate Relative	Acquisition	0.001108	0	—	1.80 K	27 Dec 2024	Gift	1,800	Insider Trading	—	Equity Shares
24 Dec 2024	Promoter	Pledge	—	—	—	10 L	19 Dec 2018	Creation	10,00,000	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	2.50 L	31 Jan 2019	Creation	12,50,000	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	1.50 L	20 May 2019	Creation	14,00,000	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	3 L	21 Jun 2019	Creation	17,00,000	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	5 L	04 Jul 2019	Creation	22,00,000	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	8 L	06 Aug 2019	Creation	30,00,000	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	3 L	23 Aug 2019	Creation	33,00,000	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	6.50 L	16 Sep 2019	Release	26,50,000	SAST	Reg31	—
24 Dec 2024	Promoter	Pledge	—	—	—	6 L	30 Sep 2019	Creation	32,50,000	SAST	Reg31	—

Wockhardt Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Wockhardt Share Price

Wockhardt Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Wockhardt Share Price

Wockhardt Share Price

Oscillators

Moving averages

Wockhardt Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Wockhardt Share Price

Corporate Actions

Company details

Wockhardt Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Wockhardt Share Price

News

Wockhardt reports higher Q1 revenue on year over year basis

Wockhardt reports higher Q1 EBITDA and stronger margin year on year

Wockhardt reports Q1 consolidated net profit after prior year loss

Wockhardt gains US FDA approval for Zaynich antibiotic for cUTI therapy

Wockhardt: Q4 Revenue 965.00 Crores Rupees Vs 740.00 Crores (Yoy)

Wockhardt Q4 EBITDA Surges to Rs 225 Crores, Margin Expands to 23.3% YoY

Wockhardt Reports Q4 Consolidated Net Profit of Rs 166 Crores vs YoY Loss.

Wockhardt's Zaynich Receives Positive CDSCO Expert Panel Nod for Gram-Negative Infection Treatment.

Wockhardt's Zaynich Receives CDSCO Expert Panel Approval for Gram-Negative Infections

Wockhardt Q3 FY2026 Results: Revenue Growth and Profitability Swing

Wockhardt Q3 FY2026 Results: EBITDA Growth Amid Consolidated Challenges

Wockhardt Q3 FY2026 Consolidated Net Profit Rises 321% YoY to Rs 59 Crores

Wockhardt Phase 3 Trial Success for Foviscu Antibiotic Demonstrates Clinical Efficacy

Wockhardt Submits WCK 5222 Marketing Application to EMA, Granted Accelerated Assessment.

Wockhardt Targets European EMA Approval for Zaynich Antibiotic by July-August 2026.

Wockhardt Receives EMA Fast-Track Designation for WCK 5222 Antibiotic Targeting Drug-Resistant Infections.

Wockhardt forms three new overseas step-down subsidiaries in Switzerland, USA

Wockhardt reports strong Q2 results with robust growth in domestic biotech business, expanding global reach.

Q2 FY26 result: Wockhardt reports year-on-year revenue decline to Rs 782 crores.

Wockhardt Q2 FY25 EBITDA rises to Rs 178 crore, margin expands sharply YoY.

Wockhardt Ltd Share Price Today

Wockhardt Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator